Neoplasm of Lung
11
2
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Trial of NanoPac Intratumoral Injection in Lung Cancer
Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Confocal Laser Endomicroscopy VERification
9-ING-41 in Patients with Advanced Cancers
Prehab for Lung and Esophageal Cancer
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Multimodalitic Imaging in the N-stage of Lung Cancer
Postoperative Analgesia With a Catheter Under the Erector Spinae Muscle for Videothoracoscopic Lung Surgery
CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility
Effect of Incidental Findings Information on Lung Cancer Screening Intent
Efficacy of Continous Regional Anesthesia Using m. Erector Spinae Catheter After VATS Procedures